For companies in the biotech space, it’s never been easy to navigate the legal and business risks inherent in a highly regulated, dynamic industry – and it’s only becoming more complicated
Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.
Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014
The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.
The WHO has concluded negotiations on a 30-page draft agreement on pandemic preparedness. It goes before the assembly for consideration in May.
Editor's Picks
